Clinical genitourinary cancer最新文献

{"title":"Efficacy of Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Study Using Propensity Score-Matched Analysis in Japan","authors":"Minori Nezasa ,&nbsp;Makoto Kawase ,&nbsp;Satoshi Washino ,&nbsp;Takato Nishino ,&nbsp;Hajime Fukushima ,&nbsp;Kosuke Iwatani ,&nbsp;Tomoaki Miyagawa ,&nbsp;Masaki Shimbo ,&nbsp;Takeshi Yamasaki ,&nbsp;Kojiro Ohba ,&nbsp;Jun Miki ,&nbsp;Kenichiro Ishida ,&nbsp;Takuya Koie","doi":"10.1016/j.clgc.2025.102346","DOIUrl":"10.1016/j.clgc.2025.102346","url":null,"abstract":"<div><h3>Introduction</h3><div>The potential improvement in oncological outcomes of robot-assisted radical prostatectomy (RARP) with neoadjuvant androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) who had high-risk or very-high risk disease (HR/VHR-PCa) remains controversial. This study evaluated the impact of neoadjuvant hormone therapy (NHT) on biochemical recurrence (BCR) following RARP.</div></div><div><h3>Materials and Methods</h3><div>A total of 1,203 patients with HR/VHR-PCa who underwent RARP at 6 centers in Japan were included. Patients were categorized into 2 groups: those who underwent RARP alone (RARP-alone group) and those who underwent RARP following NHT (NHT group). The primary endpoint was biochemical recurrence-free survival (BRFS) after RARP.</div></div><div><h3>Results</h3><div>A total of 976 patients were analyzed, including 140 patients in each group after propensity score matching. At a median follow-up of 47 months, BCR was observed in 40.7% of patients in the RARP-alone group and 31.4% in the NHT group (<em>P</em> = .106). BRFS rates did not significantly differ between the 2 groups (<em>P</em> = .671). The RARP-alone group tended to have slightly longer operative times and more positive surgical margins than the NHT group.</div></div><div><h3>Conclusion</h3><div>This study suggests that NHT does not improve BRFS in patients with HR/VHR-PCa undergoing RARP. Further research is necessary to develop more effective neoadjuvant regimens for this patient population.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102346"},"PeriodicalIF":2.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study","authors":"Ghady Bou-Nehme Sawaya ,&nbsp;Simon Tanguay ,&nbsp;Lori A. Wood ,&nbsp;Christian Kollmannsberger ,&nbsp;Naveen S. Basappa ,&nbsp;Rahul Bansal ,&nbsp;Denis Soulières ,&nbsp;Antonio Finelli ,&nbsp;Daniel Y.C. Heng ,&nbsp;Vincent Castonguay ,&nbsp;Christina Canil ,&nbsp;Eric Winquist ,&nbsp;Jeffrey Graham ,&nbsp;Georg A. Bjarnason ,&nbsp;Bimal Bhindi ,&nbsp;Aly-Khan Lalani ,&nbsp;Frédéric Pouliot ,&nbsp;Rodney H. Breau ,&nbsp;Ramy Saleh ,&nbsp;Alice Dragomir","doi":"10.1016/j.clgc.2025.102342","DOIUrl":"10.1016/j.clgc.2025.102342","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the outcomes of metastatic renal cell carcinoma (mRCC) patients, with or without sarcomatoid features, who underwent cytoreductive nephrectomy (CN) before or after systemic therapies (ST).</div></div><div><h3>Methods</h3><div>Synchronous metastatic RCC patients of IMDC intermediate- and high-risk diagnosed between January 2011 to December 2022, treated with CN before or after ST, and with histological documentation of the presence or absence of sarcomatoid features in nephrectomy specimens were identified using the Canadian Kidney Cancer information system (CKCis). Patients were classified by treatment sequence received: (1) CN after ST (2) CN before ST. Inverse probability of treatment weighting using propensity scores was used to balance for covariates. Cox proportional hazards models were used to assess the impact of initial treatment received on overall survival (OS).</div></div><div><h3>Results</h3><div>Of 709 eligible patients, 105 were treated with CN after ST and 604 with CN before ST. 75% were male, and the majority (70%) received targeted therapies (TT) used alone. In nonsarcomatoid patients (80 CN after ST and 454 CN before ST), treatment with CN after ST was associated with an improvement in OS, that was not statistically significant, compared to CN before ST (median of 60 vs. 48 months, HR 0.84, 95% CI 0.64-1.11). In sarcomatoid patients (25 CN after ST and 150 CN before ST), CN after ST was also not associated with better survival (median of 24 vs. 36 months, HR 1.10, 95% CI 0.70-1.73).</div></div><div><h3>Conclusion</h3><div>In conclusion, this study demonstrated that, no matter the sarcomatoid status, there is no statistical difference between receiving CN after ST or CN before ST. The timing of CN could potentially be linked more so to clinical assessments than the knowledge of sarcomatoid status.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102342"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity Score-Matched Analysis of Radical and Partial Nephrectomy in pT3aN0M0 Renal Cell Carcinoma","authors":"Cesare Saitta ,&nbsp;Riccardo Autorino ,&nbsp;Umberto Capitanio ,&nbsp;Giovanni Lughezzani ,&nbsp;Margaret F. Meagher ,&nbsp;Kendrick Yim ,&nbsp;Mimi V. Nguyen ,&nbsp;Matilde Mantovani ,&nbsp;Melis Guer ,&nbsp;Daniele Amparore ,&nbsp;Federico Piramide ,&nbsp;Kevin Hakimi ,&nbsp;Dattatraya Patil ,&nbsp;Hajime Tanaka ,&nbsp;Shohei Fukuda ,&nbsp;Masaki Kobayashi ,&nbsp;Wei Chen ,&nbsp;Savio D. Pandolfo ,&nbsp;Julian Cortes ,&nbsp;Dhruv Puri ,&nbsp;Ithaar H. Derweesh","doi":"10.1016/j.clgc.2025.102343","DOIUrl":"10.1016/j.clgc.2025.102343","url":null,"abstract":"<div><h3>Background</h3><div>We sought to evaluate oncological and functional outcomes of patients treated with partial nephrectomy (PN) and radical nephrectomy (RN) in pT3aN0M0 renal cell carcinoma (RCC).</div></div><div><h3>Patients and Methods</h3><div>We conducted a retrospective analysis of surgically treated pT3aN0M0 RCC patients. Primary outcome was all-cause mortality/overall survival (ACM/OS). Secondary outcomes were cancer-specific mortality/ cancer-specific survival (CSM/CSS), recurrence/progression free survival (PFS) and new onset de novo eGFR &lt; 45 mL/min/1.73 m² (CKD-S3b). A propensity score matched model in a 1:1 ratio was conducted, within a caliper width of 0.01. Kaplan–Meier analysis (KMA) and Cox multivariable analysis (MVA) were fitted to delineate survival outcomes and their predictors.</div></div><div><h3>Results</h3><div>After PSM 359 were analyzed (PN = 179 vs. RN = 180); median follow up of 38.7 (IQR 16.28-64) months. MVA for ACM revealed, high grade (HR 2.05, <em>P</em> = .019), and CKD-S3b at last follow up (HR 2.13, <em>P</em> = .018) as independent risk factors, while RN versus PN (<em>P</em> = .41) was not. MVA for CSM and recurrence revealed that RN versus PN was not an independent risk factor for CSM (<em>P</em> = .088) and recurrence (<em>P</em> = .277). MVA for CKD-S3b revealed RN versus PN (HR 1.67 <em>P</em> = .025) as associated with increased risk of CKD-S3b. KMA comparing PN versus RN revealed 5-year OS of 87.4% versus 82% (<em>P</em> = .26); 5-year CSS of 95.6% versus 90.3% (<em>P</em> = .15); 5-year PFS of 83.5% versus 77% (<em>P</em> = .38); 5-year CKD-S3b free survival of 80.8% versus 65.5% (<em>P</em> = .016).</div></div><div><h3>Conclusion</h3><div>PN exhibited oncological equipoise while reducing risk of development of eGFR &lt; 45 mL/min/1.73 m². PN may be considered in T3a RCC when prioritization of functional preservation is indicated.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102343"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Screening: Empirical Clinical Practice, Not Evidence-Based","authors":"Takeshi Takahashi","doi":"10.1016/j.clgc.2025.102341","DOIUrl":"10.1016/j.clgc.2025.102341","url":null,"abstract":"","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102341"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study","authors":"Colin Williams ,&nbsp;Andrisha-Jade Inderjeeth ,&nbsp;Wei Hong ,&nbsp;Jane McKenzie ,&nbsp;Angelyn Anton ,&nbsp;Andrew Weickhardt ,&nbsp;Shirley Wong ,&nbsp;Jeremy Shapiro ,&nbsp;Phillip Parente ,&nbsp;Jeffrey Goh ,&nbsp;Javier Torres ,&nbsp;Annabel Smith ,&nbsp;Anthony Joshua ,&nbsp;Stephen Brown ,&nbsp;Christopher Steer ,&nbsp;Julie Johns ,&nbsp;Peter Gibbs ,&nbsp;Ben Tran ,&nbsp;Arun A. Azad","doi":"10.1016/j.clgc.2025.102345","DOIUrl":"10.1016/j.clgc.2025.102345","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>There is an increasing incidence of cancer in younger patients, including prostate cancer.</div><div>Cancers developing in younger patients are reported to have a more aggressive phenotype. There is a need to examine younger patients with metastatic castration-resistant prostate cancer (mCRPC).</div></div><div><h3>Methods</h3><div>Analysis of the prospectively collected, multisite, electronic Prostate Cancer Australian Database (ePAD) was conducted to identify all mCRPC patients enrolled between June 2016 and March 2024. We defined patients diagnosed aged &lt; 55 years as younger patients (YP) and compared their characteristics, treatment patterns and outcomes to the other patients aged ≥ 55 years (OP).</div></div><div><h3>Results</h3><div>Of 915 patients with mCRPC, 59 (6%) were YP. De-novo metastatic presentation, Gleason score, presence of liver metastasis and PSA doubling time at mCRPC were similar between YP and OP. In the mCRPC setting, first line treatment with docetaxel (19% YP vs. 21% OP; <em>P</em> = .72) and ARPI (68% YP vs. 74% OP; <em>P</em> = .31) was also similar. YP were more likely to receive ≥ 3 lines of therapy for mCRPC (37% YP vs. 23% OP; <em>P</em> = .016). There was no significant difference in overall survival from start of first line therapy (median 41.9 m YP vs. 35.1 m OP; HR 0.73; 95% CI, 0.47-1.15; <em>P</em> = .17) or time-to-treatment discontinuation for ARPI (median 15.8 m YP vs. 14.9 m OP; HR 0.93; 95% CI, 0.61-1.42; <em>P</em> = .75). Age &lt; 55 was not independently associated with survival on multivariable analysis (HR 0.82; 95% CI, 0.52-1.29; <em>P</em> = .38).</div></div><div><h3>Conclusion</h3><div>Young patients with prostate cancer who go on to develop mCRPC do not appear to have distinct clinical outcomes to other patients.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102345"},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database","authors":"Aldéric Masoandro Fraslin ,&nbsp;Simone Benhamou ,&nbsp;Thierry Lebret ,&nbsp;François Radvanyi ,&nbsp;Yves Allory ,&nbsp;Maryam Karimi ,&nbsp;Julia Bonastre","doi":"10.1016/j.clgc.2025.102344","DOIUrl":"10.1016/j.clgc.2025.102344","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the incidence (all lesions) of bladder cancer (BC) in France, describe patient characteristics and healthcare pathways during the first year after diagnosis, and estimate medical costs.</div></div><div><h3>Methods</h3><div>All adult patients with an initial BC diagnosis (ICD-10 codes: C67, D09.0, D41.4) in 2017 were selected from the French National Healthcare System Database. Patients were classified according to the most invasive surgical procedure they underwent. Treatments included cystectomy, transurethral resection of bladder tumor (TURBT), intravesical therapy, chemotherapy, and radiotherapy. Healthcare pathways were analyzed as sequences and grouped using hierarchical clustering. Medical costs during the first year of the disease were estimated for each cluster.</div></div><div><h3>Results</h3><div>Out of 24,737 incident BC patients selected, the median age at diagnosis was 72 years, and 80.2% were men. Nearly 20% had received treatment for a cancer other than BC in the previous year. The majority (<em>n</em> = 9501, 38.4%) underwent TURBT only with a mean medical cost of €4435 [95% CI: 4322; 4548]. A total of 3037 patients (12.3%) underwent cystectomy as their initial treatment. The estimated costs for the group receiving intravesical instillations following a single TURBT (€6129 [5994; 6264]) were lower than those for the group with repeated TURBT (€9357 [9086; 9628]). Costs for patients who received systemic treatment after cystectomy were the highest at €25,636 [24,519; 26,752].</div></div><div><h3>Conclusion</h3><div>Our study estimates the incidence of BC in France, describes healthcare pathways at the national level, and analyses the associated economic burden.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102344"},"PeriodicalIF":2.3,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modifiable Cardiovascular Risk Factors Amongst Men With and Without Prostate Cancer in a Large, Prospective Registry","authors":"James Janopaul-Naylor ,&nbsp;Adithya K. Yadalam ,&nbsp;Jeffrey Shi Kai Chan ,&nbsp;Edward Christopher Dee ,&nbsp;Yan V. Sun ,&nbsp;Stephanie M. Cantu ,&nbsp;Anant Mandawat ,&nbsp;Sagar A. Patel","doi":"10.1016/j.clgc.2025.102340","DOIUrl":"10.1016/j.clgc.2025.102340","url":null,"abstract":"<div><h3>Introduction</h3><div>Noncancer mortality, namely cardiovascular, is the leading cause of death in men with prostate cancer. We examined modifiable risk factors for cardiovascular disease in men with and without prostate cancer.</div></div><div><h3>Patients and Methods</h3><div>We used data from the UK Biobank, a large, prospective registry, to identify 186 830 men recruited between 2006 and 2010 without missing clinical covariate data. We performed age-matched comparisons (1:5) between men with (<em>N</em> = 2 720) and without (<em>N</em> = 13 600) prostate cancer to assess for differences in modifiable cardiovascular risk factors (smoking status, lipid profile, hypertension, etc.). This analysis was repeated after stratifying for men with (<em>N</em> = 4 302) and without dyslipidemia (<em>N</em> = 12 018).</div></div><div><h3>Results</h3><div>In the overall cohort, men with prostate cancer were significantly less likely to be smokers or have diabetes than age-matched men without prostate cancer but were more likely to have higher total (<em>P</em> = .006) and low-density lipoprotein (LDL)-cholesterol (<em>P</em> = .006) levels. Cholesterol-lowering medication use did not differ between groups (<em>P</em> = .479). In the subgroup with dyslipidemia, men with prostate cancer had significantly higher total cholesterol levels (<em>P</em> = .004) without differences in cholesterol medication use (<em>P</em> = .722). In the cohort without dyslipidemia, men with prostate cancer trended toward lower active smoking (<em>P</em> = .052) and higher blood pressure medication use (<em>P</em> = .052) but had no difference in total cholesterol levels (<em>P</em> = .266).</div></div><div><h3>Conclusion</h3><div>In this analysis, we show that men with prostate cancer may have a higher total and LDL-cholesterol levels. However, cholesterol-lowering medication use may be underutilized in this population. As cardiovascular mortality is a leading cause of death in this population, integrated oncologic, cardiovascular, and primary care is paramount. Further work refining personalized, longitudinal risk factor modification is important for optimizing life expectancy in this population.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102340"},"PeriodicalIF":2.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification","authors":"Sergio Vázquez-Estévez ,&nbsp;Enrique Gallardo ,&nbsp;Ovidio Fernández-Calvo ,&nbsp;María José Juan-Fita ,&nbsp;Álvaro Montesa-Pino ,&nbsp;Martín Lázaro-Quintela ,&nbsp;Urbano Anido-Herranz ,&nbsp;Aránzazu González-del-Alba","doi":"10.1016/j.clgc.2025.102338","DOIUrl":"10.1016/j.clgc.2025.102338","url":null,"abstract":"<div><div>For patients with castration-sensitive prostate cancer (mCSPC), treatment intensification with androgen deprivation therapy (ADT) plus new androgen receptor pathway inhibitors (ARPIs) has opened a scenario where no guidance exists to indicate the best treatment after progression to metastatic castration-resistant prostate cancer (mCRPC). Clinical decision-making has become even more complex, with the proven benefit for selected patients of triplet therapy with abiraterone or darolutamide added to the double combination therapy of ADT plus docetaxel. The profile of patients for whom triple therapy would be more beneficial is being defined beyond metastatic disease presentation and volume (eg, poor prognosis features). In October 2023 and October 2024, a panel of eight Spanish medical oncologists with expertise in the management of prostate cancer met to discuss the challenges in treating mCRPC. The scientific evidence was reviewed during this meeting, knowledge and experience were shared, and controversies were discussed until a consensus was reached. This information was collected and turned into a manuscript aimed at helping clinicians determine the optimal treatment sequence after disease progression based on scientific evidence and experts’ opinions and consensus. To this end, the profile of mCSPC patients who may have received double or triplet therapy is analyzed, current treatment options are reviewed, and treatment algorithms are proposed. New and expected advancements in this field are also presented.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102338"},"PeriodicalIF":2.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Associations Between the Presence of Prostate Cancer or Testosterone Levels and Bladder Cancer Risk: A Mendelian Randomization Study","authors":"Wenbiao Ren ,&nbsp;Yewen Zhu","doi":"10.1016/j.clgc.2025.102334","DOIUrl":"10.1016/j.clgc.2025.102334","url":null,"abstract":"<div><h3>Background</h3><div>Previous observational studies and meta-analyses have indicated that prostate cancer and testosterone levels could be potential risk factors for bladder cancer. However, these studies are vulnerable to confounding variables and reverse causality. Thus, we conducted a 2-sample Mendelian Randomization (MR) study to elucidate the causal link between the presence of prostate cancer or testosterone levels and bladder cancer.</div></div><div><h3>Methods</h3><div>We acquired summary statistics for the presence of prostate cancer or testosterone levels and bladder cancer from genome-wide association studies (GWAS). MR analysis was employed to investigate the potential causal relationship between the presence of prostate cancer or testosterone levels and bladder cancer. The primary method employed was the inverse variance weighted (IVW) method, with results rigorously assessed through sensitivity analysis.</div></div><div><h3>Results</h3><div>IVW Mendelian randomization results demonstrated that prostate cancer was causally associated with an elevated risk of bladder cancer in FinnGen (OR 1.22, 95% CI, 1.13-1.31, <em>P</em> &lt; .001), UK Biobank (OR 17.9, 95% CI, 3.28-97.62, <em>P</em> &lt; .001), and the PRACTICAL database (OR 1.13, 95% CI, 1.05-1.22, <em>P</em> &lt; .001). There was no evidence of heterogeneity in the effects of genetic factors on bladder cancer risk, as indicated by Cochran's Q statistical test (FinnGen Q = 68.86, <em>P</em> = .13; UK Biobank Q = 29.05, <em>P</em> = .61; PRACTICAL Q = 108.88, <em>P</em> = .48). Sensitivity analyses confirmed the stability and robustness of the genetically determined risk effect of prostate cancer on bladder cancer. However, there was no causal link between testosterone levels and bladder cancer (<em>P</em> &gt; .05).</div></div><div><h3>Conclusions</h3><div>This study identified that genetically predicted prostate cancer was causally linked to an increased risk of bladder cancer. Appropriate measures should be taken to prevent the subsequent development of bladder cancer in patients with prostate cancer.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102334"},"PeriodicalIF":2.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteoporosis Amongst Testicular Cancer Survivors: Long Term Follow-Up of the Veterans Affairs Health System","authors":"Nuphat Yodkhunnatham ,&nbsp;Paul Riviere ,&nbsp;Kshitij Pandit ,&nbsp;Kylie Morgan ,&nbsp;Margaret Meagher ,&nbsp;Mai Dabbas ,&nbsp;Tyler Nelson ,&nbsp;Dhruv Puri ,&nbsp;Kit Yuen ,&nbsp;Jacob Taylor ,&nbsp;Daniel Herchenhorn ,&nbsp;Heather Hofflich ,&nbsp;Tyler Stewart ,&nbsp;Juan Javier-Desloges ,&nbsp;Amirali Salmasi ,&nbsp;Rana R. McKay ,&nbsp;Sean Q. Kern ,&nbsp;Frederick Millard ,&nbsp;Brent Rose ,&nbsp;Aditya Bagrodia","doi":"10.1016/j.clgc.2025.102332","DOIUrl":"10.1016/j.clgc.2025.102332","url":null,"abstract":"<div><h3>Introduction</h3><div>Testicular cancer (TC) is the most common malignancy among young males and is associated with cure rates over 95%. However, the long-term health implications of treatments, such as the risk of osteoporosis, remain inadequately understood. This study aims to explore the incidence of osteoporosis in TC survivors and associated risk factors.</div></div><div><h3>Methods</h3><div>This retrospective study utilized data from the Veterans Affairs (VA) national electronic health record system, identifying 1686 TC patients and 7412 matched noncancer controls. The incidence of osteoporosis was determined through diagnosis codes and osteoporosis medication prescriptions. Statistical analyses, including chi-squared tests, t-tests, and Cox proportional hazards models, were employed to evaluate risk factors.</div></div><div><h3>Results</h3><div>TC survivors exhibited a significantly elevated hazard of developing osteoporosis (HR =2.18; 95% CI, 1.52-3.14; <em>P</em> &lt; .001), which persisted after adjusting for covariates (HR = 1.58; 95% CI, 0.99-2.51; <em>P</em> = .013). There was no significant TC treatment-specific effect: neither radiation nor chemotherapy were associated with an increased hazard of osteoporosis in multivariable analysis.</div></div><div><h3>Conclusion</h3><div>TC survivors face a higher hazard of osteoporosis, with age at diagnosis being a significant factor. These findings highlight the need for regular bone health monitoring in TC survivors. Future prospective studies are necessary to validate these results and better understand the mechanisms linking TC, hypogonadism, and osteoporosis risk.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 3","pages":"Article 102332"},"PeriodicalIF":2.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}